The present disclosure relates to the compound of formula (I) (cabazitaxel): which may be in the form of an anhydrous base, a hydrate or a solvate, for its use for the treatment of pediatric cancers. In one embodiment, the solvate is an acetone solvate having 5% to 8% by weight of acetone.